300142 Stock Overview
Researches, develops, produces, and markets vaccines in China.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Walvax Biotechnology Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥11.33 |
52 Week High | CN¥28.45 |
52 Week Low | CN¥10.81 |
Beta | 0.58 |
11 Month Change | -12.17% |
3 Month Change | -27.65% |
1 Year Change | -54.99% |
33 Year Change | -82.47% |
5 Year Change | -58.11% |
Change since IPO | 1.43% |
Recent News & Updates
Recent updates
Shareholder Returns
300142 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -0.4% | -4.1% | -1.4% |
1Y | -55.0% | -25.0% | -19.1% |
Return vs Industry: 300142 underperformed the CN Biotechs industry which returned -25% over the past year.
Return vs Market: 300142 underperformed the CN Market which returned -19.1% over the past year.
Price Volatility
300142 volatility | |
---|---|
300142 Average Weekly Movement | 4.9% |
Biotechs Industry Average Movement | 6.3% |
Market Average Movement | 6.6% |
10% most volatile stocks in CN Market | 10.0% |
10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 300142's share price has been volatile over the past 3 months.
Volatility Over Time: 300142's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 2,388 | Runsheng Jiang | www.walvax.com |
Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococcal polysaccharide vaccine, for individuals age 2 years of pneumococcal diseases; ACYW135 meningococcal polysaccharide vaccine, for the prevention of invasive meningococcal diseases; Group A and C meningococcal polysaccharide vaccine, for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium neisseria meningitidis; Group A and Group C meningococcal conjugate vaccine, for the prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for children 3 months through 5 years of age. It also provides haemophilus influenzae type b conjugate vaccine, for the prevention of invasive infections for children 2 months through 5 years of age; diphtheria, tetanus, and acellular pertussis combined vaccine, for diphtheria and tetanus for infants and children 3 months through 6 years of age.
Walvax Biotechnology Co., Ltd. Fundamentals Summary
300142 fundamental statistics | |
---|---|
Market cap | CN¥18.10b |
Earnings (TTM) | CN¥261.53m |
Revenue (TTM) | CN¥3.88b |
69.2x
P/E Ratio4.7x
P/S RatioIs 300142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
300142 income statement (TTM) | |
---|---|
Revenue | CN¥3.88b |
Cost of Revenue | CN¥739.43m |
Gross Profit | CN¥3.14b |
Other Expenses | CN¥2.88b |
Earnings | CN¥261.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
Earnings per share (EPS) | 0.16 |
Gross Margin | 80.94% |
Net Profit Margin | 6.74% |
Debt/Equity Ratio | 6.9% |
How did 300142 perform over the long term?
See historical performance and comparison